Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KANAMYCIN SULFATE vs BACITRACIN-NEOMYCIN-POLYMYXIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing m RNA misreading.
Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin and polymyxin B are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis, while polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides and phospholipids, leading to increased permeability and cell death.
Short-term treatment of serious infections caused by susceptible strains of bacteria (e.g., Escherichia coli, Proteus species, Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter species),Adjunctive therapy in staphylococcal infections,Mycobacterium tuberculosis infections (as second-line agent)
Treatment of superficial bacterial infections of the skin and mucous membranes (e.g., wounds, burns, impetigo, folliculitis),Prophylaxis of minor skin abrasions and wounds to prevent infection,Off-label: Use in conjunctival irrigation or ophthalmic infections (as combination ophthalmic preparations)
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
Apply topically to affected area 2-5 times daily.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (Cr Cl <10 m L/min).
Bacitracin: 1.5 hours (prolonged in renal impairment); Neomycin: 2-3 hours (accumulates with renal dysfunction); Polymyxin B: 6-9 hours (increased in renal impairment).
Not metabolized; excreted unchanged by glomerular filtration.
Not extensively metabolized. Systemic absorption from topical application is minimal; absorbed drug may undergo hepatic metabolism or be excreted renally unchanged.
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Bacitracin: primarily renal (>90% unchanged); Neomycin: renal (30-50% unchanged) with non-renal clearance; Polymyxin: renal excretion of parent drug (60-80% unchanged) with some biliary and fecal elimination.
Low; approximately 0-10%, primarily to albumin.
Bacitracin: <10% bound to plasma proteins; Neomycin: 0-30% bound; Polymyxin B: 50-70% bound, primarily to alpha-1-acid glycoprotein and lipoproteins.
0.2-0.4 L/kg; reflects distribution primarily into extracellular fluid.
Bacitracin: 0.3 L/kg (confined to extracellular fluid); Neomycin: 0.2-0.3 L/kg (low tissue penetration except renal cortex); Polymyxin B: 0.7-1.0 L/kg (extensive tissue binding).
Intramuscular: ~100%; Oral: <1% (not absorbed); Ophthalmic: minimal systemic absorption (<1%).
Oral: negligible (<1%) for all three components; topical: minimal systemic absorption via intact skin (<0.5%); ophthalmic/otic: minimal absorption via mucosal surfaces.
GFR 50-90 m L/min: administer every 24 hours. GFR 10-50 m L/min: administer every 24-72 hours. GFR <10 m L/min: administer every 72-96 hours. Dose adjustments based on serum concentrations.
No systemic absorption; no dosage adjustment required.
No dose adjustment required for hepatic impairment. Kanamycin is primarily renally eliminated.
No systemic absorption; no dosage adjustment required.
Neonates: 7.5-10 mg/kg IV every 12 hours. Infants and children: 15 mg/kg/day IM or IV divided every 8-12 hours. Maximum total daily dose: 1.5 g.
Apply topically to affected area 2-5 times daily; same as adult dose.
Lower initial and maintenance doses due to age-related decrease in renal function. Monitor renal function and serum concentrations closely. Consider dosing based on ideal body weight and renal function.
Apply topically to affected area 2-5 times daily; same as adult dose.
Boxed warnings: Neurotoxicity (ototoxicity vestibular and auditory), nephrotoxicity, and neuromuscular blockade. Risk increases with high doses, prolonged use, renal impairment, and concurrent use of other ototoxic/nephrotoxic drugs. Monitor renal function and drug levels. Avoid in pregnancy.
Not applicable for topical formulations. However, systemic use of bacitracin (rare) may cause nephrotoxicity and anaphylactic reactions. Neomycin may cause ototoxicity and nephrotoxicity with systemic absorption.
Ototoxicity (vestibular and auditory) can be irreversible, especially with renal impairment, high doses, prolonged therapy, or concurrent ototoxic drugs. Nephrotoxicity risk; monitor renal function and serum drug levels. Neuromuscular blockade risk, especially with anesthetics, neuromuscular blocking agents, or in patients with neuromuscular disorders. Superinfection, Clostridium difficile diarrhea. Use caution in elderly, dehydration, and pre-existing renal impairment.
Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Topical use may cause allergic contact dermatitis, especially with neomycin.,Avoid application to large areas, open wounds, or damaged skin due to potential systemic absorption and toxicity.,Use with caution in patients with renal impairment or pre-existing hearing loss (neomycin component).,Ototoxicity and nephrotoxicity may occur if significant systemic absorption occurs.
Hypersensitivity to kanamycin or other aminoglycosides; myasthenia gravis (increased risk of neuromuscular blockade).
Hypersensitivity to any component (bacitracin, neomycin, polymyxin B) or other aminoglycosides/polypeptide antibiotics.,Ophthalmic use in eyes with corneal abrasions or perforation (relative).,Known history of neomycin-associated ototoxicity or nephrotoxicity.
No significant food interactions known. Kanamycin absorption is not affected by food. However, maintain adequate hydration.
No significant food interactions; topical application minimizes systemic absorption. No dietary restrictions.
First trimester: No evidence of teratogenicity in humans, but crosses placenta and may cause fetal ototoxicity. Second and third trimesters: Risk of fetal ototoxicity (irreversible bilateral hearing loss) and nephrotoxicity, especially with prolonged or high-dose therapy.
Bacitracin-Neomycin-Polymyxin is a topical combination with negligible systemic absorption; thus, fetal risk is minimal. No known teratogenic effects reported; animal studies for individual components show no fetal harm at systemic doses. However, neomycin has theoretical risk of ototoxicity if systemically absorbed, but topical use is considered low risk. FDA Pregnancy Category C for components, but topical use deemed safe.
Excreted into breast milk in small amounts; M/P ratio not established. Use caution in breastfeeding due to potential for infant ototoxicity and nephrotoxicity; monitor infant for diarrhea, rash, and hearing loss.
Minimal systemic absorption after topical application; excretion into breast milk is unlikely. M/P ratio not determined; safe for use during breastfeeding if applied to small areas and not to open wounds.
No standard dosing adjustment required for pregnancy; however, increased volume of distribution may require higher loading doses. Tight therapeutic drug monitoring indicated due to altered renal clearance.
No dosing adjustments necessary for pregnancy. Pharmacokinetic changes due to pregnancy (e.g., increased skin blood flow, hydration) are not clinically significant for this topical combination. Standard topical application is appropriate.
Kanamycin is an aminoglycoside antibiotic used primarily for serious Gram-negative infections. Monitor peak and trough levels to avoid ototoxicity and nephrotoxicity; typical therapeutic peaks: 15-30 mcg/m L, troughs <5 mcg/m L. Avoid concurrent use with other nephrotoxic or ototoxic drugs (e.g., furosemide, vancomycin, cisplatin). Adjust dose in renal impairment using creatinine clearance. Intramuscular administration preferred; avoid rapid IV push. Use with caution in myasthenia gravis or Parkinson's disease due to neuromuscular blockade potential.
Triple antibiotic ointment (bactiracin-neomycin-polymyxin) is first-line for prophylaxis of minor skin infections; avoid use on large areas, deep wounds, or burns due to risk of systemic absorption and nephrotoxicity. Neomycin carries high risk of allergic contact dermatitis; consider alternative in patients with known hypersensitivity. Topical use only; not for ophthalmic or intranasal application due to polymyxin ocular toxicity. Synergistic coverage includes Gram-positive (bacitracin), Gram-negative (polymyxin), and broad-spectrum (neomycin).
Complete the entire course of therapy even if you feel better.,Report any hearing loss, tinnitus, dizziness, or changes in urination immediately.,Stay well hydrated unless instructed otherwise.,Avoid taking other medications without consulting your doctor, especially diuretics or other antibiotics.,This medication may cause nausea; take with food if tolerated.
Apply a thin layer to clean, minor cuts, scrapes, or burns 1-3 times daily.,Do not use on large body areas, deep puncture wounds, animal bites, or serious burns.,Stop use and consult doctor if rash, irritation, or signs of infection (worsening redness, swelling, pus) develop.,Avoid use on eyes, nose, or mouth; if contact occurs, rinse thoroughly with water.,Tell your doctor if you have kidney problems or are allergic to any of the ingredients (bacitracin, neomycin, polymyxin B).
"Kanamycin, an aminoglycoside antibiotic, may reduce the renal clearance of Lornoxicam, a nonsteroidal anti-inflammatory drug (NSAID), by competitively inhibiting tubular secretion or altering renal perfusion. This interaction can lead to elevated serum levels of Lornoxicam, increasing the risk of dose-dependent adverse effects such as gastrointestinal bleeding, renal impairment, and central nervous system toxicity. Clinically, patients may present with worsening renal function or NSAID-related side effects, especially in those with pre-existing renal compromise or dehydration."
"Kanamycin, an aminoglycoside antibiotic, increases the nephrotoxic potential of Cisplatin, a platinum-based chemotherapeutic agent, through additive damage to the proximal renal tubules. This synergistic effect elevates the risk of acute kidney injury, particularly in patients with pre-existing renal impairment or those receiving other nephrotoxic drugs. Clinically, this interaction may lead to reduced renal function, electrolyte imbalances, and delayed elimination of both agents, potentially exacerbating systemic toxicity."
"The coadministration of Kanamycin and Vancomycin results in synergistic nephrotoxicity due to additive insult to the proximal renal tubules. Both aminoglycoside and glycopeptide antibiotics accumulate in the renal cortex, causing tubular cell necrosis and acute kidney injury (AKI). This interaction significantly increases the risk of renal impairment, potentially leading to irreversible kidney damage, particularly in patients with pre-existing renal compromise, advanced age, or prolonged therapy."
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Bacitracin."
"Bacitracin may increase the nephrotoxic activities of Colistimethate."
"Bacitracin may increase the nephrotoxic activities of Streptomycin."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KANAMYCIN SULFATE vs BACITRACIN-NEOMYCIN-POLYMYXIN, answered by our medical review team.
KANAMYCIN SULFATE is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing m RNA misreading.. BACITRACIN-NEOMYCIN-POLYMYXIN is a Aminoglycoside Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin and polymyxin B are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis, while polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides and phospholipids, leading to increased permeability and cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KANAMYCIN SULFATE and BACITRACIN-NEOMYCIN-POLYMYXIN depend on the specific clinical indication. These are both Aminoglycoside Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KANAMYCIN SULFATE is: 15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.. The standard adult dose of BACITRACIN-NEOMYCIN-POLYMYXIN is: Apply topically to affected area 2-5 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining KANAMYCIN SULFATE and BACITRACIN-NEOMYCIN-POLYMYXIN. Bacitracin may increase the nephrotoxic activities of Kanamycin. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. KANAMYCIN SULFATE is classified as Category C. First trimester: No evidence of teratogenicity in humans, but crosses placenta and may cause fetal ototoxicity. Second and third trimesters: Risk of fetal ototoxicity (irreversible. BACITRACIN-NEOMYCIN-POLYMYXIN is classified as Category A/B. Bacitracin-Neomycin-Polymyxin is a topical combination with negligible systemic absorption; thus, fetal risk is minimal. No known teratogenic effects reported; animal studies for i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.